27 completed, 7 unknown, 6 active not recruiting, 5 terminated. 18 Phase 1, 17 Phase 2, 14 Phase 3, 2 Not applicable, 2 Phase 4.
Follow Wet Age-related Macular Degeneration: new trials by email Literature Review of Wet Age-related Macular Degeneration trials Research Report on Wet Age-related Macular Degeneration
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 3 Study of Intravitreal OLN324 in Adults With Neovascular (Wet) Age-related Macular Degeneration (nAMD) (OLN324-CP-05) OLN324, Ranibizumab - Wet Age-related Macular Degeneration | Phase 3 | Not yet recruiting | Ollin Biosciences, Inc. | 400 | 2026-10-15 | 2026-09-11 |
| User-centric Study of Patients' Receptiveness Towards the Web-based Automated Vision Impairment Gaze-tracking Analysis Systems Age-Related Macular Degeneration, Wet Age-related Macular Degeneration | Enrolling by invitation | Tan Tock Seng Hospital | 30 | 2026-04-01 | 2026-10-02 | |
| Evaluating the Safety and Preliminary Efficacy of EXG202 Gene Therapy for Neovascular AMD EXG202 injection - Wet Age-related Macular Degeneration | Phase 1 / Phase 2 | Not yet recruiting | Guangzhou Jiayin Biotech Ltd | 60 | 2025-10-16 | 2025-09-17 |
| To Evaluate the Safety and Preliminary Efficacy of Intravitreal EXG202 Injection in Patients with Wet (neovascular) Age-related Macular Degeneration (wAMD) EXG202 - Wet Age-related Macular Degeneration (wAMD), Wet Age-related Macular Degeneration | Early Phase 1 | Not yet recruiting | Guangzhou Jiayin Biotech Ltd | 8 | 2025-03-28 | 2025-03-21 |
| A Long-term Follow up Study of EXG102-031 in Participants With wAMD No intervention, only for observational studies - Wet Age-related Macular Degeneration | Recruiting | Guangzhou Jiayin Biotech Ltd | 42 | 2025-03-13 | 2025-08-15 | |
| A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK Tarcocimab tedromer, Tabirafusp tedromer, Aflibercept - Wet Age-related Macular Degeneration | Phase 3 | Active not recruiting | Kodiak Sciences Inc | 675 | 2024-08-23 | 2026-04-29 |
| Automated Vision Assessment and Impairment Detection Through Gaze Analysis in Wet AMD Patients Automated Vision Assessment and Impairment Detection through Gaze Analysis (AVIGA) system - Age-Related Macular Degeneration, Wet Age-related Macular Degeneration | Active not recruiting | Tan Tock Seng Hospital | 128 | 2023-04-18 | 2026-01-08 | |
| Comparing Efficacy of 8-Week and 12-Week Faricimab Initial Follow-Up Treatment Intervals Faricimab Injection - Wet Age-related Macular Degeneration | Phase 4 | Recruiting | Faculty Hospital Kralovske Vinohrady | 100 | 2023-03-31 | 2025-03-13 |
| Efficacy and Safety of RC28-E Versus Aflibercept RC28-E, Aflibercept - Wet Age-related Macular Degeneration | Phase 3 | Unknown | RemeGen Co., Ltd. | 432 | 2023-03-14 | 2023-08-31 |
| This Study Will Compare the Efficacy and Safety of SCT510A Administered by Intravitreal Injection (IVT) With Ranibizumab in Patients With wAMD Ranibizumab, SCT510A - Wet Age-related Macular Degeneration | Phase 3 | Unknown | Sinocelltech Ltd. | 446 | 2023-02-14 | 2023-02-16 |
| Pharmacogenomics of antiVEGF in Patients With Age-Associated Macular Degeneration (AMD) Bevacizumab, Ranibizumab Ophthalmic - Wet Age-related Macular Degeneration | Phase 3 | Recruiting | Parc de Salut Mar | 630 | 2022-11-18 | 2025-11-20 |
| Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) EYP-1901, Aflibercept 2mg/0.05mL Inj,Oph - Wet Age-related Macular Degeneration | Phase 2 | Completed | EyePoint Pharmaceuticals, Inc. | 161 | 2022-06-30 | 2025-10-15 |
| Comparison of Rapid Aflibercept and Brolucizumab T&E in wAMD Aflibercept, Brolucizumab, early treat and extend (T&E) - Wet Age-related Macular Degeneration | Not applicable | Active not recruiting | Berner Augenklinik | 80 | 2022-05-09 | 2025-12-08 |
| Study of SCB-420 in Subjects With Neovascular Age-related Macular Degeneration SCB-420, Aflibercept - Wet Age-related Macular Degeneration | Phase 1 | Withdrawn | Clover Biopharmaceuticals AUS Pty | 2022-04-01 | 2022-04-19 | |
| A Study to Compare JL14002 to Lucentis® in Subjects With Wet Age-related Macular Degeneration (wAMD) JL14002 monoclonal antibody(Fixed dosing regimen), Ranibizumab(Fixed dosing regimen), JL14002 monoclonal antibody(PRN) - Wet Age-related Macular Degeneration | Phase 3 | Completed | Jecho Biopharmaceuticals Co., Ltd. | 443 | 2022-03-01 | 2026-02-05 |
| Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2, Aflibercept (EYLEA®) - AMD, nAMD | Phase 3 | Active not recruiting | AbbVie | 735 | 2022-01-13 | 2026-08-03 |
| A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) KSI-301, Aflibercept, Sham Procedure - Wet Age-related Macular Degeneration | Phase 3 | Completed | Kodiak Sciences Inc | 557 | 2021-06-23 | 2024-07-03 |
| Phase I Study to Compare CMAB818 Injection and Lucentis® in Patients With Wet AMD CMAB818, Lucentis® - Wet Age-related Macular Degeneration | Phase 1 | Completed | Shanghai Biomabs Pharmaceutical Co., Ltd. | 24 | 2021-06-03 | 2024-03-28 |
| A Study to Evaluate the Efficacy and Safety of MW02 in the Treatment of nAMD MW02, Lucentis - Wet Age-related Macular Degeneration | Phase 2 / Phase 3 | Unknown | Mabwell (Shanghai) Bioscience Co., Ltd. | 433 | 2021-05-07 | 2022-03-28 |
| RGX-314 Gene Therapy Pharmacodynamic Study for Neovascular Age-related Macular Degeneration (nAMD) RGX-314 - Neovascular Age-related Macular Degeneration, Wet Macular Degeneration | Phase 2 | Completed | AbbVie | 60 | 2021-02-22 | 2024-09-05 |
Showing 20 of 56. Sign in to see all of them.
Macular Degeneration (14) · Eye Diseases (9) · Retinal Diseases (8) · Wet Macular Degeneration (7) · Retinal Degeneration (6) · Choroidal Neovascularization (4) · Blindness (2) · Geographic Atrophy (1) · Glycogen Storage Disease Type II (1) · Neovascularization, Pathologic (1) · Retinal Vein Occlusion (1) · Vision Disorders (1) · Vision, Low (1)
Retinal Degeneration (11) · Retinal Diseases (10) · Eye Diseases (9) · Pathological Conditions, Signs and Symptoms (7) · Eye Diseases, Hereditary (6) · Metaplasia (5) · Pathologic Processes (5) · Choroid Diseases (4) · Neovascularization, Pathologic (4) · Nervous System Diseases (4) · Uveal Diseases (4) · Macular Degeneration (3) · Neurologic Manifestations (3) · Sensation Disorders (3) · Signs and Symptoms (3)
aflibercept (17) · Ranibizumab (12) · Bevacizumab (4) · Adrenal Cortex Hormones (1) · Doxycycline (1) · Drug Delivery Systems (1) · Injections (1) · MP0112 (1) · Prednisolone (1) · RC28-E protein (1) · Single Person (1) · brolucizumab (1) · canakinumab (1) · faricimab (1) · vatalanib (1)
Bayer (4) · AbbVie (3) · Guangzhou Jiayin Biotech Ltd (3) · Kodiak Sciences Inc (3) · Oraya Therapeutics, Inc. (3) · Adverum Biotechnologies, Inc. (2) · Alkahest, Inc. (2) · EyePoint Pharmaceuticals, Inc. (2) · Novartis (2) · Novartis Pharmaceuticals (2) · Qilu Pharmaceutical Co., Ltd. (2) · RemeGen Co., Ltd. (2) · Sinocelltech Ltd. (2) · Tan Tock Seng Hospital (2) · Allergan (1)
United States (18) · China (13) · United Kingdom (6) · Switzerland (5) · Czechia (4) · Germany (4) · Hungary (4) · Italy (4) · Spain (4) · Australia (3) · Canada (3) · France (3) · Japan (3) · Puerto Rico (3) · Belgium (2)
Pablo Velazquez-Martin, MD (3) · Augustinus Laude, MBChB (2) · Denis O'Shaughnessy, Ph.D. (2) · Zheng Kuang Noel Soh, BSc (2) · Byung Jhip Ha (1) · David M Brown, MD (1) · Elliott H Sohn, MD (1) · Jeffrey A Nau, MMS (1) · Jeffrey Heier, MD (1) · Jeffrey S Heier, MD (1) · Justus G. Garweg, Prof. Dr. med. (1)
PMID 10588299, PMID 18439679, PMID 18577497, PMID 22173073, PMID 22840421, PMID 22895887, PMID 24211172, PMID 24385141, PMID 24907435, PMID 28268575, PMID 29060394, PMID 29060564, PMID 32844399, PMID 37987893, PMID 38152412, PMID 38198053, PMID 38554726, PMID 38881599, PMID 39719502
2019 (2)